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Most MRI studies of Alzheimer’s disease (AD) and frontotemporal dementia (FTD) have assessed structural, perfusion and
diﬀusion abnormalities separately while ignoring the relationships across imaging modalities. This paper aimed to assess brain
gray (GM) and white matter (WM) abnormalities jointly to elucidate diﬀerences in abnormal MRI patterns between the diseases.
Twenty AD, 20 FTD patients, and 21 healthy control subjects were imaged using a 4Tesla MRI. GM loss and GM hypoperfusion
weremeasuredusinghigh-resolutionT1andarterialspinlabelingMRI(ASL-MRI).WMdegradationwasmeasuredwithdiﬀusion
tensor imaging (DTI). Using a new analytical approach, the study found greater WM degenerations in FTD than AD at mild
abnormality levels. Furthermore, the GM loss and WM degeneration exceeded the reduced perfusion in FTD whereas, in AD,
structuraland functional damages were similar.Joint assessments of multimodal MRIhave potential value to providenew imaging
markers for improved diﬀerential diagnoses between FTD and AD.
1.Introduction
Alzheimer’s disease (AD) and frontotemporal dementia
(FTD) are two of the most common and devastating dis-
orders that result in dementia in the elderly population.
Although the deﬁnitive diagnosis of each type of dementia
is not possible until autopsy, biomarkers based on magnetic
resonance imaging (MRI), providing measurements of brain
volume, perfusion, and white matter integrity, have been
promising for improved diagnosis and prediction of demen-
tia progression [1]. In AD, which is a progressive dementing
disorder associated with cognitive impairments beginning
with episodic memory deﬁcits, MRI measurements of brain
volume have shown characteristic gray matter (GM) loss pri-
marily in medial temporal lobe regions [2, 3] whereas func-
tionalstudiesusingarterialspinlabelingMRIorPET/SPECT
imaging have shown prominent changes primarily in the
parietallobe(includingtheposteriorcingulategyrusandlat-
eral temporoparietal areas) [4–7], though regions of struc-
tural, and functional alterations can overlap. Furthermore,
diﬀusion tensor imaging (DTI), a unique method to assess
the integrity of white matter microstructure, have revealed
white matter (WM) alterations in AD, involving the parietal,
temporal, and frontal brain regions [8–13]. In FTD, which is
associated with impairments of social behaviors, personality,
and executive functions, MRI has shown characteristic pat-
t e r n so fs t r u c t u r a lG Ml o s s[ 14, 15] and GM dysfunction
[16–20] primarily in frontal and anterior temporal lobes.
WM volume loss [21, 22] and WM degradation in FTD
[23–25] have also been reported in the frontal and temporal
regions.
Using biomarkers of neurocognitive measurements to
diﬀerentiate between AD and FTD are often diﬃcult because
of overlapping symptoms. Several studies using imaging
markers compared diﬀerences in abnormal brain patterns
between AD and FTD directly. Structural MRI showed that2 International Journal of Alzheimer’s Disease
AD was associated with greater GM loss than FTD in pos-
terior brain regions [26, 27] whereas FTD was associated
with more severe GM loss than was AD in frontal brain
regions [26, 28–30]. Similarly, functional imaging such as
PET/SPECT and perfusion MRI showed that AD was associ-
ated with greater reduced cerebral blood ﬂow or metabolism
than FTD in parietal and occipital brain regions [16, 28,
30–32]; whereas FTD was associated with greater frontal
dysfunction than AD [16, 30, 32]. In addition to diﬀerences
i nG M ,w eh a v ep r e v i o u s l yr e p o r t e dd i ﬀerences in WM be-
t w e e nA Da n dF T D[ 25]. Speciﬁcally, measurements of
fractional anisotropy (FA)—a summary measure of DTI
indexing WM integrity—indicated greater WM degradation
(FA reduction) of frontal brain regions in FTD compared
to AD. Furthermore, no brain region in AD was shown to
have more WM degradation when compared to FTD. Taken
together, these ﬁndings suggest that AD and FTD are each
associated with disease-speciﬁc regional patterns of GM and
WM alterations. Recent multimodality strategies [33, 34]
of combined radiological markers such as analyzing brain
volume and perfusion or WM changes together have shown
superior power than that using conventional single modality
domain(e.g.,brainvolumemeasurementalone)indiagnosis
of AD. However, to our knowledge, rarely did MRI studies
evaluate GM and WM diﬀerences between AD and FTD
jointly.
In this study we present a new approach to compare
structural, perfusion, and diﬀusion alterations between AD
and FTD using T1-weighted high-resolution structural MRI,
arterial spin-labeled perfusion MRI (ASL-MRI), and DTI.
The objective was to determine if a joint evaluation of
multimodal MRI could provide a biomarker for a diﬀerential
diagnosis between AD and FTD.
2.SubjectsandMethods
2.1. Subjects. Twenty AD patients (mean age and standard
deviation: 63.1±6.9 yrs) with a Mini-Mental State Examina-
tion (MMSE) [35] score of on average 21.9 ±5.6, 20 patients
with FTD (age: 60.7 ± 9.9y r s ;M M S E :2 3 .1 ± 5.6) and 21
cognitivelynormal(CN)subjects(age:61.9±9.6yrs;MMSE:
29.6 ± 0.5) were included in this cross-sectional MRI study.
Asummaryofthesubjectdemographicsandrelevantclinical
information are listed in Table 1. The patients with FTD and
AD were recruited from the Memory and Aging Center of
the University of California, San Francisco. All patients were
diagnosed based on information obtained from an extensive
clinical history and physical examination. The MR images
were used to rule out other major neuropathologies such as
tumors, strokes, or inﬂammation but not to diagnose de-
mentia. The subjects were included in the study if they
were between 30–80 years old and without history of brain
trauma, brain tumor, stroke, epilepsy, alcoholism, psychi-
atric illness, or other systemic diseases that aﬀect brain
function. FTD was diagnosed according to the consensus
criteria established by Neary et al. [36]. All FTD patients
were diagnosed with the frontal variant subtype, two of
which had combined motor neuron-related symptoms. AD
patients were diagnosed according to the criteria of the
National Institute of Neurological and Communicative Dis-
ordersandStroke-Alzheimer’sDiseaseandRelatedDisorders
Association (NINCDS/ADRDA) [37]. All subjects received
a standard battery of neuropsychological tests including
assessment of global cognitive impairment using MMSE and
global functional impairment using the Clinical Dementia
Rating(CDR)scale[38].Fifty-sevenoutofall61subjectshad
blood drawn for APOE genotyping. Reliable information
abouttheageofonsetofsymptomswasavailablefrom12out
of 20 AD patients and from all 20 FTD patients. Because it is
not unusual for subjects in this age group to have WM signal
hyperintensities (WMSH) on MRI, subjects with WMSH
were included. An experienced radiologist reviewed all MRI
data, and the scores of WMSH were used as covariates in
the analysis. The severity of WMSH was classiﬁed as mild
(deep white matter lesions ≤3mm, and periventricular hy-
perintensities <5mm thickness), moderate (deep white
matterlesionsbetween4–10mm,orperiventricularhyperin-
tensities between 6–10mm thickness), or severe (deep white
matter lesions >10mm, or periventricular hyperintensities
>10mm thickness), according to the Scheltens’ rating scale
[39]. All subjects or their legal guardians gave written in-
formed consent before participating in the study, which was
approved by the Committees of Human Research at the
University of California and the VA Medical Center at San
Francisco.
2.2. Data Acquisition. All scans were preformed on a 4
Tesla (Bruker/Siemens) MRI system with a single housing
birdcage transmit and 8-channel receive coil. T1-weighted
images were obtained using a 3D volumetric magnetization
prepared rapid gradient echo (MPRAGE) sequence with TR/
TE/TI = 2300/3/950ms, 7-degree ﬂip angle, 1.0 × 1.0
× 1.0mm3 resolution, 157 continuous sagittal slices. In
addition,FLAIR(ﬂuidattenuatedinversionrecovery)images
with timing TR/TE/TI = 5000/355/1900ms were acquired to
facilitate the evaluation of WMSH. Perfusion images were
acquired using a continuous arterial spin labeling (cASL)
sequence [40] with a single-shot echo-planar imaging (EPI)
part to map the perfusion signal. cASL-MRI was performed
with TR/TE = 5200/9ms with 2-second long labeling pulses
andaone-secondpostlabelingdelay.Sixteensliceswith5mm
slice thickness and 1.2mm interslice gap, 3.75 × 3.75mm2
in-plane resolution were acquired. DTI was acquired based
on a dual spin-echo EPI sequence supplemented with two-
fold parallel imaging acceleration (GRAPPA) [41]t or e d u c e
susceptibility distortions. Other imaging parameters were
TR/TE = 6000/77ms, ﬁeld of view 256 × 224cm, 128 ×
112 matrix size, yielding 2 × 2mm 2 in-plane resolution, 40
slices each 3mm thick. One reference image (b = 0) and
six diﬀusion-weighted images (b = 800s/mm2, along 6
noncollinear directions) were acquired.
2.3. Data Analyses. The assessment of brain volume changes
were performed using SPM8 software (http://www.ﬁl.ion
.ucl.ac.uk/spm/software/spm8/) based on an “optimized”
VBM procedure described by Ashburner and Friston [42].
The procedure included several steps. (1) Tissue segmen-
tation: An expectation maximization segmentation (EMS)International Journal of Alzheimer’s Disease 3
Table 1: Demographic and clinical data summary.
Normal AD FTD
Number of subjects 21 20 20
Age (years) 61.9 ±9.66 3 .1 ±6.96 0 .7 ± 9.9
Age range (years) 33∼73 51∼73 32∼74
Sex (M:F) 11:10 11:9 13:7
Years of Education (years) 16.8 ±2.51 5 .7 ±3.01 6 .2 ± 3.2
MMSE 29.6 ±0.52 1 .9 ±5.62 3 .1 ± 5.6
CDR 0 0.8 ±0.31 .2 ±0.6
APOE-ε4 (carriers: non-carriers) 3:17a 14:5a 7:11 b
Age of onset (years) NA 56.2 ±5.7c 55.1 ± 9.9
Symptom duration (years) NA 3.25 ±1.6c 5.3 ±4.9
WMSH(severe:moderate:mild) 3:2:16 1:4:15 2:2:16
avalue for one subject is missing.
bvalue for two subjects is missing.
cv a l u ef o r8s u b j e c t si sm i s s i n g .
WMSH = white matter signal hyperintensities.
algorithm [43] was applied to obtain probabilistic maps
of GM, WM, and CSF from the T1-weighted MRI data.
(2) Spatial normalization: ﬁrst, customized GM and WM
prior images were created by transforming GM and WM
probabilistic maps of all subjects into the standard MNI
(Montreal Neurological Institute) space [42]. The segmented
GM probabilistic maps in their native spaces were then
spatiallynormalizedagaintothecustomizedGMpriorimage
using a nonlinear transformation with 16 interactions. (3)
Jacobian modulation: the spatially normalized GM images
were multiplied by the Jacobian determinants of the trans-
formation (modulation) to obtain volume diﬀerences. (4)
Smoothing: the modulated GM images were smoothed with
an 8mm full-width-at-half-maximum (FWHM) isotropic
Gaussian kernel to reduce variations from misregistrations
and to perform voxelwise image statistics.
Theassessmentofperfusionchangesincludedthefollow-
ing steps. (1) Cerebral blood ﬂow (CBF) image calculation:
a perfusion weighted (PWI) image was created by pairwise
subtraction of coregistered labeled from unlabeled ASL im-
ages. The PWI images were then scaled to obtain a quan-
titative CBF image based on a single compartment perfusion
model [44]. (2) Intermodality coregistration: ALS perfusion
and the corresponding T2- and T1-weighted image were
coregistered using an aﬃne alignment to establish anatomi-
cal correspondence between CBF and segmented GM images
and to compute partial volume-corrected CBF in GM.
(3) Partial volume correction: partial volume correction of
CBF images was performed by rescaling CBF in each voxel
proportionately to the GM and WM content, assuming that
perfusion of white matter is only 25% of that of GM, as
detailed by Du et al. [16]. (4) Spatial normalization: the
partial volume-corrected CBF images in GM were spatially
normalized to the customized GM prior image that was
createdfromthepreviousprocessingofVBM,usingthesame
nonlinear transformation and smoothing parameters.
The assessment of white matter integrity was performed
based on DTI and computation of fractional anisotropy
(FA) maps, using the dTV.II software [45] and Volume-one
software package (URL: http://www.ut-radiology.umin.jp/
people/masutani/dTV.htm), supplemented by automatic
image denoising and eddy-current corrections. SPM8 soft-
ware was used for voxelwise analysis of the FA images as
outlined in detail elsewhere [25]. In brief, the FA images
in the native space underwent the following procedures. (1)
Creation of a customized FA template: an averaged FA image
was ﬁrst created from all subjects’ FA images that initially
transformed to the EPI-derived MNI template in SPM. This
averagedFAimagewasfurtherco-registeredtotheWMprior
image using aﬃne alignment and manual adjustment [46]t o
archive a customized FA template that accurately correspond
to the anatomical information in the WM prior image.
(2) Spatial normalization and smoothing: the FA image of
each subject in the native space was recursively normalized
to the customized FA template using the same nonlinear
transformation and smoothing parameters that were applied
in the previous VBM procedure.
2.4. Statistics. Paired group diﬀerences were evaluated voxel-
by-voxel using a general linear model with diagnosis as main
contrastandage,sex,andtheyearsofeducationascovariates.
In addition, total intracranial volume (TIV) was used as a
covariate in test for volume diﬀerences and global mean
perfusion was used as a covariate in test for perfusion dif-
ferences. A threshold of at least 85% GM volume fraction
in voxels was applied to restrict GM volume and perfusion
analysestovoxelscontainingpredominantlyGM.Similarly,a
thresholdofatleast80%WMvolumefractionwasappliedto
restrict FA analysis to voxels containing predominantly WM.
The statistical signiﬁcance for main eﬀects of abnormalities,
which was only the prestep for joint analyses, was set to an
uncorrected voxel-level P value of .001.
To test if FTDand ADdiﬀer withrespecttoWMandGM
abnormalities, we started bydetermining the number of vox-
els representing “abnormal” values for each patient and each
MRI modality. This was conducted by recording voxelwise
diﬀerences between an individual’s image value (GM vol-
ume, GM perfusion, or WM FA) and the respective mean4 International Journal of Alzheimer’s Disease
value of the control group. The diﬀerence was then nor-
malized to the standard error of the control mean value to
express abnormality as a T-score [47]. High T-scores rep-
resent high abnormalities beyond the normal ranges. Next,
the number of “abnormal” voxels above a T-score threshold
was recorded and normalized to the total number of GM or
WM voxels to account for each patient and each modality
to quantify the extent of brain abnormality. We termed the
number of normalized “abnormal” voxels load.D i ﬀerences
in loads between AD and FTD patients were evaluated sta-
tistically via permutation test with 1000-fold completely
random resampling of the diagnostic labels (AD and FTD),
usingtheRproject(http://www.r-project.org/).Thestatistics
on the loads were evaluated for T-score values ranging from
−2 (indicating a mild abnormality level) to −6 (indicating a
severeabnormalitylevel).Usingthepermutationtest,wealso
assessed whether the load from a speciﬁc MRI modality (e.g.,
WM FA) relative to another (e.g., GM loss) modality, termed
conditional load,d i ﬀered within and across the diagnosis
groups. The level of signiﬁcance for permutation tests was
set at P = .05.
3. Results
3.1. Demographic Clinical Data. As shown in Table 1, there
were no signiﬁcant diﬀerences in age, sex, years of education,
and severity of WMSH between each patient group (AD or
FTD) and controls. AD and FTD patients had signiﬁcant
lower MMSE (P<. 001, by ANOVA test) scores compared
with controls, as expected. Furthermore, AD patients had a
greater proportion of APOE-ε4c a r r i e r st h a nC N( P = .04
by χ2 test) but the FTD patients did not (P = .35 by χ2
test) when compared to CN. AD and FTD patients did not
diﬀersigniﬁcantlywithrespecttoage,sex,yearsofeducation,
MMSE, CDR, age of onset, symptom duration, and severity
of WMSH. To avoid further reductions in sample size due
to the missing values, we did not perform the joint analysis
including the age of onset or the APOE-ε4 genotyping as
covariates across all MRI modalities, although symptom
duration was associated with GM volume loss within the
FTD group.
3.2. Spatial Distribution of MRI Abnormalities in AD and
FTD Compared to CN. Figures 1(a)–1(d) depict the regional
distributionsofGMloss(inwarmcolor),GMhypoperfusion
(in green color), and reduced WM FA (in blue color) in AD
and FTD, compared to CN, respectively, as well as the direct
comparisonsbetweenADandFTD,basedonvoxel-wisetests
prior to the joint analysis. For better visualization of regional
relations, the various distributions are overlaid on each other
in Figure 1(d).
Compared to CN, AD patients showed widespread GM
loss in bilateral parietal and temporal lobes. The left tem-
poroparietal lobes had the most prominent GM loss. Other
regions of GM loss in AD included the posterior cingulate
gyrus, thalamus, and bilateral occipital lobes. Compared to
CN, FTD patients showed GM loss predominantly in bi-
lateral frontal and temporal lobes. The right frontoinsular
gyrus showed the most prominent GM loss. Other regions
of GM loss included limbic lobes such as bilateral anterior
cingulate gyrus, uncus, subcortical nuclei including the bi-
lateral caudate and the thalamus, and the lateral parietal
lobes. Comparing FTD and AD directly, patients with AD
showed more GM loss than FTD in bilateral occipital gyrus,
left precuneus whereas FTD showed more GM loss in bi-
lateral frontal lobes, including the orbital gyrus, inferior and
medial frontal gyrus, and anterior cingulate gyrus.
Regarding perfusion, AD patients showed reductions re-
lative to CN in bilateral temporoparietal lobes, including su-
perior temporal gyrus, precuneus and posterior cingulate
gyrus. Hypoperfusion in AD was most pronounced in the
left temporal gyrus. Compared to CN, FTD patients showed
reduced perfusion in bilateral frontal lobes, including infe-
rior, medial, and superior frontal gyrus, anterior cingulate
gyrus, and thalamus. Hypoperfusion in FTD was most pro-
nounced in the right inferior frontal gyrus. Compared to
FTD, AD patients showed signiﬁcant hypoperfusion in the
left superior temporal gyrus, claustrum; whereas compared
to AD, FTD patients had signiﬁcant hypoperfusion in right
superior, middle, and bilateral medial frontal gyrus.
Regarding WM FA, AD patients had FA reductions
relative to CN bilaterally in WM regions in parietal, tem-
poral, and some frontal lobe regions. The periventricular
deep WM, posterior corpus callosum and the left posterior
cingulum exhibited the most prominent FA reductions. In
contrast,FTDpatientshadwidespreadFAreductionsrelative
to CN bilaterally in frontal and temporal lobes, and the
anterior corpus callosum, and bilateral anterior cingulum
were prominently involved. Compared to AD, FTD patients
had lower FA values bilaterally in frontal deep WM, anterior
corpus callosum and bilateral anterior cingulum, whereas
AD patients showed no region with signiﬁcantly lower FA
values when compared to the FTD group.
3.3. Diﬀerences between AD and FTD in GM Volume,
P e r f u s i o n ,o rW MD a m a g e .We ﬁrst tested if loads diﬀered
between AD and FTD. Figure 2(a) displays the loads of GM
loss (2A-I), GM hypoperfusion (2A-II), and WM FA (2A-
III) reduction, respectively, in AD and FTD over a range of
T-score levels (deviation from normal). The signiﬁcance of
diﬀerences in the loads b e t w e e nA Da n dF T Da saf u n c t i o n
of T-scores is plotted in Figure 2(b), and separately for each
type(G MV o l ,G MP e rf,W MF A )o fload. Note, theloads and
the P values are plotted on a logarithmic scale and increasing
negative T-scores indicate increasing deviation from normal
values. This demonstrates that there is a signiﬁcantly greater
load of WM FA reduction in FTD compared to AD at mild
abnormality levels (up to T-scores of about −2.3) while the
signiﬁcance gradually vanishes at more severe abnormality
levels. There is a trend (P = .07 to .1) towards more
GM loss in FTD compared to AD at moderate to severe
abnormalitylevels(T-scores< −4).H o w ev er ,theload ofGM
hypoperfusion does not diﬀer signiﬁcantly between AD and
FTD across the range of T-scores.
3.4. Joint Assessment of GM Volume, Perfusion, and WM FA
DamagesinADorFTD. Figure3showstheconditionalloads
(the load in one MRI modality relative to another) overInternational Journal of Alzheimer’s Disease 5
FTD< CN AD< CN
AD< FTD FTD< AD
L. R.
T:−3.3 −9
(a)
FTD< CN AD< CN
AD< FTD FTD< AD
L. R.
T:−3.3 −9 R. L.
(b)
FTD< CN AD< CN
AD< FTD FTD< AD L. R.
T:−3.3 −9
No diﬀerences
(c)
FTD< CN AD< CN
AD< FTD FTD< AD L. R.
L. R.
(d)
Figure 1: Signiﬁcance maps of systematic brain abnormalities in FTD and AD patients relative to control subjects (AD <C Nand FTD <
CN), and direct comparisons between AD and FTD (AD <F T Dand FTD <A D ). (a) GM loss (warm color) and (b) GM hypoperfusion
(green color) overlaid on a surface rendered brain template. (c) Reduced WM FA (blue color) in AD or FTD overlaid on an axial brain
template. (d) Overlay of the abnormal distributions together. The signiﬁcant threshold was Puncorrected <. 001 for all voxelwise tests. Color
scales indicated ranges of signiﬁcance (T-scores) upon the P threshold.
a range of abnormality levels (T-scores) separately for AD
(Figure 3(a)) and for FTD (Figure 3(b)). Note, the plots in
Figures 3(a) and 3(b) are on a logarithmic scale. Accordingly,
a conditional load larger than 1 indicates that the load of a
particular modality is greater than the load of the reference
modality, whereas a value smaller than 1 indicates that the
load of the reference is greater than particular modality. The
extent to which diﬀerences in one load (on particular mo-
dality) relative to another (on reference modality) are above
chance is depicted in Figures 3(c) and 3(d) for AD and FTD,
respectively.Noteagain,P-valuesinFigures3(c)and3(d)are
plotted on a logarithmic scale of the base-10 logarithm. The
loads of GM volume loss relative to GM hypoperfusion as a
function of severity (T-scores) are displayed in brown lines,
r e d u c e dW MF Ar e l a t i v et oG Mh y p o p e r f u s i o ni np u r p l e
l i n e s ,a n dG Mv o l u m el o s sr e l a t i v et oW MF Ai nr e dl i n e s .
Figures 3(a) and 3(c) show that in AD, the loads of the
diﬀerent modalities are not signiﬁcantly diﬀerent compared
to each other across the level of abnormalities (T-scores)
levels. In FTD, by contrast (Figures 3(b) and 3(d)), the
load of GM volume loss as well as the load of reduced
WM FA are each signiﬁcantly greater relative to the load
of GM hypoperfusion at lower levels of abnormality (up
to T-scores = −4). However, as abnormality increases (T-
scores < −4), the signiﬁcance of the diﬀerence in the load
of GM volume loss or WM FA reductions relative to GM
hypoperfusion gradually disappears. There are no signiﬁcant
diﬀerences between the load of GM loss and the load of WM
FAreductionsacrossallrangesofabnormalitieslevelsinFTD
patients.
3.5. Diﬀerences between AD and FTD in Joint Modalities.
Finally, we also tested if AD and FTD diﬀered with regard
to their conditional loads from a particular modality relative
to that from reference modality but found no signiﬁcant
diﬀerence between the groups (P>. 1) across all ranges of
the abnormalities (T-score) levels.6 International Journal of Alzheimer’s Disease
AD
FTD
AD
FTD
AD
FTD
−6 −5 −4 −3 −2 −6 −5 −4        3 − − 2 −6 −5 −4 −3 −2
0.01
0.1
1
10
100
0.01
0.1
1
10
100
0.01
0.1
1
10
100
L
 
o
a
d
o
f
G
M
h
y
p
o
p
e
r
f
u
s
i
o
n
(
%
)
(
l
o
g
)
L
o
a
d
o
f
G
M
v
o
l
u
m
e
l
o
s
s
(
%
)
(
l
o
g
)
L
o
a
d
o
f
W
M
F
A
r
e
d
u
c
t
i
o
n
(
%
)
(
l
o
g
)
Ts c o r e Ts c o r e -- Ts c o r e -
(a)
−6 −5 −4 −3 −2
0.001
0.01
0.1
1
10
GM vol
GM perf
WM FA
P =.05
Ts c o r e
P
v
a
l
u
e
s
(
l
o
g
)
-
(b)
Figure 2: Diﬀerences in loads of GM loss (orange lines), GM hypoperfusion (green lines), and reduced WM FA (blue lines) between FTD
and AD across a range of T-scores and signiﬁcant levels. (a) Mean loads of GM loss (I), GM hypoperfusion (II), and reduced WM FA (III)
along a range of abnormality levels (T-scores) in AD (solid lines) and FTD (dash lines) patients. (b) Variations in signiﬁcance of the load
diﬀerences between FTD and AD as a function of T-scores. Note, the vertical axis of all plots in (a, b) uses a base-10 logarithmic scale. The
horizontal dotted line indicates P = .05 signiﬁcance.
4. Discussion
We have two main ﬁndings. First, FTD patients exhibited
more WM damage than AD patients at mild abnormality
levels(i.e.,smallT-scores).Thediﬀerencevanishedgradually
for more severe abnormality levels (i.e., larger T-scores).
Second, FTD patients had greater GM loss and WM damage
relative to GM hypoperfusion, although the diﬀerences of
damage between modalities gradually vanished with increas-
ing levels of abnormality. In contrast to FTD, AD patients
had equal damage in all three modalities, irrespective of the
level of abnormality. Taken together, the results suggest that
FTD and AD diﬀer in amount of WM and GM structural
and functional damages, in addition to their characteristic
regional patterns of brain alterations than healthy controls.
Our ﬁrst main ﬁnding of greater WM damage in FTD
than AD at mild levels of abnormality suggests that WM
may be more sensitive to the pathology of FTD than to the
pathology of AD at their early disease stages. The hallmark of
FTD is tauopathies or ubiquitin immunoreactive inclusions
by the presences of neuronal and glial inclusions [48, 49]i n
gray and white matter. WM pathologies in FTD have been
reported with astrocytic gliosis and oligodendroglial apopto-
sis, which may ultimately result in axonal degeneration [50–
53]. A recent study [54] also reported that oligodendroglial
pathology can be predominant in FTD despite severe GM
damage. On the other hand, degeneration of frontostriatal
networks, which is a characteristic feature of FTD [26], sug-
gests that WM denegation in anterior brain could also be a
primary FTD pathology. In contrast to FTD, the hallmark of
AD is the deposition of amyloid plaques and neuroﬁbrillary
tangles that are associated with loss of neurons and synapses
[55, 56]. WM pathology in AD has been suggested to occur
secondarily to GM pathology and may include reduction
of myelin, axons, and oligodendrocytes [57, 58]. A vascular
origin of WM pathology in AD has also been suggested [59].
However,WMpathologiesinADareusuallyconsideredmild
andpotentiallyreversible[60].Interestingly,ourdatashowed
that diﬀerences in WM damage between AD and FTD dis-
appearedathigherabnormalitylevels.Itispossibletosuggest
that AD and FTD undergo similar WM pathologies at a
severe brain damage level. One explanation is that severe
WM abnormalities are an outcome of irreversible vascular
damage, such as appearance of WMSH, which aﬀects AD
and FTD similarly [61]. Another possible explanation is that
WM changes resulting from degeneration of corticocortical
connections may inevitably occur in both AD and FTD.
In addition, we found a trend of more GM loss in FTD
than AD at moderate to severe levels of abnormality.
This observation is consistent with histopathological studies
showing substantial loss of spindle neurons in the cortex in
F T Db u tn o ti nA D[ 62]. The ﬁnding is also in agreement
with several MRI studies [29, 30, 63, 64]w h i c hc o m p a r e d
FTD and AD directly, showing regionally greater GM loss in
FTD when compared to AD but no greater GM loss in AD
when compared to FTD. Similarly, several longitudinal stu-
dies reported greaterratesof GM atrophyin FTDwhencom-
pared to AD [65, 66]. However, some MRI studies [26, 67]
r e p o r t e dg r e a t e rG Ml o s si nA Dc o m p a r e dt oF T D ,t h o u g h
the extent of the GM losses varied regionally. The discrep-
a n c ym a yr e s u l tf r o mn o t o r i o u sd i ﬃculties to adequately
match impairment severity in FTD and AD given substantial
diﬀerences in symptomatology, although our current study
attempted to match the severities (such as the measures of
CDR, MMSE) of AD and FTD groups as closely as possible.
The second major ﬁnding that GM loss and WM damage
exceed perfusion damage in FTD may be explained by loss
of brain tissue other than neurons contributing to GM atro-
phy in FTD. Information about diﬀerential loss of various
types of brain tissue may be particularly relevant in earlierInternational Journal of Alzheimer’s Disease 7
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Figure 3: Conditional load of one modality relative to another as a function of the level of abnormality (T-score) for AD (a) and FTD (b).
Note,verticalaxesin(a)and(b)areplottedonalogarithmicscale(base-10)whereavaluelargerthanoneindicatestheload fromaparticular
modality was higher than the load from reference modality. Conditional load lower than 1 indicated opposite relations between modalities.
The extent to which diﬀerences in the conditional loads among modalities are above chance (P<. 05) across the level of abnormality is
indicated in plot (c) for AD and in plot (d) for FTD. Note, P values in (c) and (d) are also plotted on a logarithmic scale. The horizontal dash
lines indicate P = .05 signiﬁcance.
and potentially reversible stages of the disease. Our ﬁndings
are supported by several histopathological studies demon-
strating that the earliest cellular changes in FTD occur in as-
trocytes without neuron loss and that neuronal damage
becomes more prominent in later stages of the disease
[50, 68]. Therefore, at mild abnormality levels of FTD, the
surviving neurons may still function normally as reﬂected by
the normal levels of perfusion. Our ﬁndings are consistent
with other studies carried out in our laboratory [69]a n do n
diﬀerent cohorts of FTD and AD patients which have
implied dissociation between GM atrophy and perfusion.
Speciﬁcally, these studies indicated that FTD was associated
with greater GM atrophy in absence of signiﬁcant reduction
ofperfusion.TheseresultscontrasttheﬁndingsinAD,where
the abnormalities across the three modalities were all similar.
Our voxelwise analysis demonstrates the regional pat-
terns of GM loss, hypoperfusion, and reduced WM FA in
this sample of AD and FTD patients are consistent with the
disease-speciﬁc patterns that have been reported in previous
MRI studies of brain structure [14, 70], perfusion [5, 6], and
DTI [25, 71–73]. Furthermore, the similarity between the
regional patterns of GM and WM alterations which appear
in the same lobe together for each disease, implies that WM
degradation mirrors that of GM damages and is consistent
with previous reports [74]. Taken together, these results can
demonstrate the well-documented pathological bases of AD
[56]a n dF T D[ 68].
The new joint analysis approach allows for the investiga-
tion of diﬀerent abnormalities across multiple MRI modal-
ities such as structural, perfusion and diﬀusion MRI between
groups. The approach can be used to test whether groups
diﬀerwithrespecttoasingleMRImeasureaswellasmultiple
measures. The approach was augmented by nonparametric
statistical tests via permutations and carried out across8 International Journal of Alzheimer’s Disease
a range of T-scores to reduce measurement bias toward the
various brain conditions. The concept can be expanded in
principle to conduct a voxelwise joint analysis of multiple
MRI measures to determine regional variations in GM loss
and hypoperfusion. Other statistical methods for joint anal-
yses of multiple image modalities such as joint independent
component analysis (jICA) [75] may provide alternative
solutions. The ﬁndings with multimodal MRI could poten-
tially be useful to improve the design of AD and FTD clinical
trialsinvolvingMRI.First,correlationsacrosstheMRImeas-
ures, potentially boosting sensitivity and speciﬁcity, could
lead to reduced sample sizes. Second, the ﬁnding revealed
that FTD presents more white matter involvement relative
to AD, thus providing a new biological feature of FTD, and
could be used to relax the need to match disease severity in
studies recruiting AD and FTD patients.
Limitations of the current study include a small sample
size that was reliant on clinical diagnoses which were not
suﬃciently conﬁrmed by autopsies. Therefore, conﬁdence
in the generalization of the results is limited, and potential
misdiagnosis of patients may have resulted in spurious ﬁnd-
ings. Furthermore, we cannot completely rule out that other
factors than disease etiology, such as genetic proﬁles, dura-
tion of symptoms, and cardiovascular conditions, which
contributed to MRI diﬀerences between the patients and
thus contaminated the ﬁndings. Second, diﬀusion encoding
was limited to the minimum of 6 directions at the time this
protocol was initiated, although it is known that many more
encoding directions improve the characterization of diﬀu-
sion such as fewer ambiguities in regions of crossing ﬁbers
and better spatial invariance of the noise pattern. Therefore,
ﬁber crossings and the DTI noise pattern may potentially
mimic regional diﬀerences in FA between these groups.
Third, we ignored relationships between brain regions in
our joint analysis and therefore under-utilized information
from the multimodal MRI data. A more powerful statistical
framework [76] that takes spatial relations between mul-
tivariate measures into account may provide more power.
Finally, the data was artiﬁcially scaled to provide a uniform
resolution for all MRI modalities, which may have induced
a spatial bias as well as altered selectively the sensitivity of
each modality. Other approaches that do not require a uni-
form resolution but can operate on variable spatial scales,
such as information theoretic formalisms [77], may lead to
diﬀerences in results.
In conclusion, our ﬁndings suggest that FTD and AD
diﬀerregardingtheirimpactsonWMandGMstructuraland
functional abnormalities, in addition to diﬀerences between
theircharacteristicregionalpatternsofbrainalterations.Fur-
thermore, the joint assessment of multimodal MRI measures
employed in this study has potential value to improve the
diﬀerential diagnosis between FTD and AD.
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